Tsai Li-Kai, Lin Huey-Juan, Chua Su-Kiat, Liao Pen-Chih, Yang Yuan-Po, Chou Ping-Chen, Lee Chun-Wei, Lin Mao-Jen, Chen Hsi-Ming, Yeh Jung-Tze, Li Yi-Heng
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
Department of Neurology, Chi Mei Medical Center, Tainan, Taiwan.
J Stroke Cerebrovasc Dis. 2018 Feb;27(2):e27-e33. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.044. Epub 2017 Nov 6.
This study aims to observe the effectiveness and safety of idarucizumab in dabigatran-treated patients with severe bleeding or requiring surgery in Taiwan.
In Taiwan, 11 dabigatran-treated patients developed severe bleeding, fracture that needed surgery, and acute ischemic stroke requiring thrombolysis. These patients were treated with idarucizumab and obtained adequate hemostasis. Our experiences reconfirmed the efficacy and safety of idarucizumab in Asian patients.
Idarucizumab improves safety in dabigatran-treated patients. Continued education about the availability and appropriate use of idarucizumab is necessary in Asia.
本研究旨在观察依达赛珠单抗在台湾接受达比加群治疗且发生严重出血或需要手术的患者中的有效性和安全性。
在台湾，11例接受达比加群治疗的患者发生了严重出血、需要手术的骨折以及需要溶栓的急性缺血性卒中。这些患者接受了依达赛珠单抗治疗并实现了充分止血。我们的经验再次证实了依达赛珠单抗在亚洲患者中的疗效和安全性。
依达赛珠单抗可提高接受达比加群治疗患者的安全性。在亚洲，有必要持续开展关于依达赛珠单抗的可及性和合理使用的教育。
